Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$16000.0.

  • Ernexa Therapeutics' Gains from Investment Securities rose 9807.46% to -$16000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $470000.0, marking a year-over-year increase of 10974.7%. This contributed to the annual value of -$414000.0 for FY2024, which is 5917.16% up from last year.
  • Ernexa Therapeutics' Gains from Investment Securities amounted to -$16000.0 in Q3 2025, which was up 9807.46% from $4000.0 recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Gains from Investment Securities registered a high of $5.2 million during Q1 2022, and its lowest value of -$3.9 million during Q4 2023.
  • Its 5-year average for Gains from Investment Securities is -$21866.7, with a median of -$16000.0 in 2025.
  • As far as peak fluctuations go, Ernexa Therapeutics' Gains from Investment Securities surged by 73158.54% in 2022, and later plummeted by 405500.0% in 2024.
  • Over the past 5 years, Ernexa Therapeutics' Gains from Investment Securities (Quarter) stood at $70000.0 in 2021, then plummeted by 531.43% to -$302000.0 in 2022, then plummeted by 1199.67% to -$3.9 million in 2023, then skyrocketed by 112.31% to $483000.0 in 2024, then crashed by 103.31% to -$16000.0 in 2025.
  • Its Gains from Investment Securities stands at -$16000.0 for Q3 2025, versus $4000.0 for Q2 2025 and -$1000.0 for Q1 2025.